Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
577 participants
OBSERVATIONAL
2021-09-14
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary aim is to study the impact of the pandemic on asthma control in children aged 3-16 years with a medical diagnosis of asthma, compared to data from other observational cohorts conducted in the same region prior to the pandemic.
A sub-population of children 3-16 years will be assessed at exacerbation and at a follow-up visit, 2-4 months later, with clinical data, biological and microbiological samples.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Data will be compared to data from other observational cohorts conducted in the same region prior to the pandemic.
A sub-population of children 3-16 years will be assessed at exacerbation and at a follow-up visit, 2-4 months later, with clinical data, biological and microbiological samples.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
population included in the VIRASTHMA COVID G4 study
No interventions assigned to this group
Group 2
population included in the previous studies "VIRASTHMA", "CHAMPIASTHMA" (IRDCB No.: 2019-A03310-57), "COBRAPED" (NCT02114034), "VIRASTHMA 2" (IRDCB No.: 2014 A01687 40, NCT: 03960359), "INCOVPED" (pediatric emergencies, NCT04336761).
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With a medical diagnosis of asthma as per-guidelines, who had been followed-up for at least 6 months,
* Assessed in one of the pediatric departments participating in the study,
* After written consent of at least one of the 2 parents and/or representative of the parental authority, and of the child if he is older than 8 years old.
Criteria for the sub-population assessed at "exacerbation" and second visit:
* Children and adolescents aged 3 to 16 years
* With a medical diagnosis of asthma as per-guidelines, who had been followed-up for at least 6 months,
* Hospitalized for a severe asthma exacerbation (requiring hospitalization and general corticosteroid therapy) at Lille University Hospital
* After written consent of both parents and/or representative of the parental authority, and of the child if he is over 8 years old
Exclusion Criteria
* Inability of parents to receive informed information, inability to participate in the entire study, refusal to sign the consent form
3 Years
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stéphanie Lejeune, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Lille
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Stephanie Lejeune, MD, PHD
Role: primary
Antoine Deschildre, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A03365-34
Identifier Type: OTHER
Identifier Source: secondary_id
2020_85
Identifier Type: -
Identifier Source: org_study_id